Abstract. Endometrial stromal sarcoma (ESS) occurs rarely and accounts for only 0.2% of all uterine malignancies.
Introduction
Uterine sarcomas are uncommon tumors, accounting for 2-3% of all uterine neoplasms (1) . Among the uterine sarcomas, endometrial stromal sarcoma (ESS) accounts for 10% of all tumors, representing ~0.2% of all uterine malignancies, with an incidence of ~2 cases per million women per year (2) . The tumors originate from the mesenchymal component of the endometrium and are characterized by a proliferation of cells with endometrial stromal (ES) cell differentiation. ESS is divided into low-and high-grade tumors according to cell morphology, mitotic rates, cellularity and the presence of necrosis. Recently, the term 'undifferentiated endometrial sarcoma' has been proposed for the World Health Organization classification of tumors instead of the term 'high-grade endometrial stromal sarcoma' due to the absence of original ES components in the tumor type (3, 4) .
The initial treatment of choice for low-grade ESS is a hysterectomy with bilateral salpingo-oophorectomy. The role of adjuvant therapy, such as radiotherapy, chemotherapy or hormonal treatment, is not fully established (5) . While the prognosis of low-grade ESS is favorable, with a 5-year overall survival of >90%, the recurrence-free survival rate is markedly lower at ~50% (6, 7) .
Hormonal therapy, such as use of progestins (megestrol acetate and medroxyprogesterone acetate), has been used widely for advanced and recurrent ESS, as the majority of low-grade ESS express estrogen receptors (ERs) and progesterone receptors (PRs) (8) . However, progestins can cause edema, weight gain, vaginal bleeding, hypertension and thromboembolic problems (9) .
There are several anecdotal reports of low-grade ESS that responded to aromatase inhibitors, particularly the third generation of these drugs, with more favorable toxicity profiles and thus a wider therapeutic index (6, 9) . However, due to the rarity of these tumors, there are no prospective or large retrospective studies on aromatase inhibitor use in the treatment of low-grade ESS. The present study reviewed the literature for data on aromatase inhibitor use in patients with low-grade ESS, including data from the present study on the cases of two patients with residual or recurrent low-grade ESS who experienced long-term disease-free survival following treatment with letrozole. All patients provided written informed consent to undergo therapy and publish the current case report.
Case report

Patient 1.
A 51-year-old female, who presented to Chungnam National University Hospital (Daejeon, South Korea) with lower abdominal pain and vaginal bleeding, underwent a total abdominal hysterectomy with bilateral salpingo-oophorectomy in August 2007 for presumed adenomyosis. The final histology revealed a low-grade ESS of the uterus. The tumor immunostaining was strongly positive for ER and PR (ER: ++, 70%; PR: +, 40%). Positron emission tomography/computed tomography (CT) showed increased glucose metabolism at the small nodules in the presacral space, rectovaginal space and right common iliac lymph node. The patient received palliative chemotherapy, consisting of three cycles of paclitaxel (175 mg/m 2 ) and cisplatin (60 mg/m 2 ) between September and October 2007, but showed disease progression. In late November 2007, the patient underwent secondary debulking surgery, including a pelvic lymph node dissection, appendectomy, partial omentectomy and para-aortic lymph node dissection. In December 2007, the patient was referred to the Department of Internal Medicine for post-operative letrozole treatment, as follows. A baseline abdominopelvic CT scan revealed a small amount of ascites fluid and peritoneal seeding with an increased cancer antigen-125 (CA-125) level of 87.7 U/ml (normal range, 0-35 U/ml). The patient was started on letrozole at a daily dose of 2.5 mg. The CA-125 level normalized after 1 month of letrozole and a CT scan revealed a complete response (CR) after 3 months of the drug treatment. The patient has experienced a complete response to this therapy for 80 months, with no significant drug toxicity.
Patient 2.
A 49-year-old female, who had known uterine myomas, visited Chungnam National University Hospital due to vaginal bleeding in August 2009. A magnetic resonance imaging scan of the pelvis revealed two large heterogeneous uterine masses. The patient underwent a total abdominal hysterectomy with bilateral salpingo-oophorectomy, pelvic lymph node dissection and para-aortic lymph node dissection for presumed uterine leiomyosarcoma. Histopathological examination revealed a low-grade ESS with tumor emboli in the periadnexal soft tissue. An immunohistochemical profile revealed positivity for ER (++, 80%) and PR (++, 80%) and the post-operative CA-125 level was 65.8 U/ml. Between August and November 2009, the patient was prescribed medroxyprogesterone acetate at a daily dose of 1,000 mg. The CA-125 level was normalized after 2 months of this treatment, with no evidence of disease on abdominopelvic CT scans. However, the patient discontinued the medication 1 month later due to the adverse side-effects of weight gain and hypertension. The patient was then started on 2.5 mg letrozole daily. The patient has experienced a CR for 57 months, with no adverse events.
Literature review
Method. For a systematic review, a search was performed of the English-language literature for reports of cases of low-grade ESS treated with aromatase inhibitors. The systematic review was undertaken in MEDLINE/PubMed using the key words 'endometrial stromal sarcoma' combined with 'aromatase inhibitor.' Separate searches were then performed for 'uterine sarcoma', and 'endometrial sarcoma' combined with 'aromatase inhibitor'. The relevant studies were examined and reviewed, and any cited literature that had not been identified previously was also included and evaluated. Any patients with high-grade ESS were excluded. The primary outcome of this literature review was to evaluate the response rates of patients with low-grade ESS who were treated with aromatase inhibitors. The secondary outcomes included duration of aromatase inhibitor treatment. Treatment outcomes were defined as CR, partial response (PR), stable disease (SD) or progressive disease (PD), based on the Response Evaluation Criteria In Solid Tumors (version 1.0) (10) . Duration of aromatase treatment was defined as the interval from the date of initiation of aromatase inhibitor treatment to the date of discontinuation, mortality or last follow-up.
Statistical analysis. Categorical variables were analyzed using linear-by-linear association. For all analyses, P<0.05 was considered to indicate a statistically significant difference. All statistical analyses were conducted using the SPSS software (version 17.0; SPSS Inc., Chicago, IL, USA).
Characteristics and treatment outcomes of patients treated with aromatase inhibitors.
In total, 30 patients with recurrent or residual low-grade ESS, who were treated with aromatase inhibitors, including the 2 patients of the present study (patients 1 and 2), were identified. Table I shows the patient characteristics and treatment outcomes of those individuals with low-grade ESS who were treated with aromatase inhibitors (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . The age of the patients at the time of starting aromatase inhibitor treatment ranged from 28 to 87 years (mean age, 53 years). The duration of aromatase inhibitor treatment ranged from 1.5 to 168 months (median, 26.5 months). In total, 3 patients were administered more than one aromatase inhibitor (patients 5, 29 and 30). Of the 30 patients, 28 patient cases had the outcome recorded. The response rate to aromatase inhibitors in the evaluable patients is listed in Table II . The overall response rate to all aromatase inhibitors was 77.4% and the disease control rate was 90.3% if patients 5, 29 and 30 are counted twice, once for each treatment (n=31). A total of 8 patients (25.8%) experienced a complete response, 16 (51.6%) experienced a partial response, 4 (12.9%) exhibited stable disease and 3 (9.7%) experienced progressive disease. Among the aromatase inhibitors, letrozole was most widely used and appeared to be effective (overall response rate, 85.7%). The association between response rate and the line of aromatase inhibitor treatment was also examined (Table III) . The overall response rate of first-line aromatase inhibitor treatment (11/13; 84.6%) was slightly higher than that of treatment with aromatase inhibitors of second-line or higher (13/18; 72.2%), but the difference was not statistically significant (P= 0.453). Aromatase inhibitors appear to be well tolerated, with a remarkably low incidence of side-effects. Only 2 patients experienced side-effects serious enough for discontinuation of the aromatase inhibitor. Patient 5 was treated with aminoglutethimide, a first-generation aromatase inhibitor, and suffered from asthenia and diarrhea. However, the patient showed a CR without side-effects over a long period once prescribed letrozole, a third-generation aromatase inhibitor. Patient 26, who was treated with anastrozole for 9 months, experienced arthritis with joint dysfunction and discontinued use of the drug. c Includes duration of response to megesterol. Letrozole was administered at 2.5 mg daily; aminoglutethimide was administered at 500 mg four times a day; anastrozole was administered at 1 mg daily; and exemestane was administered at 25 mg daily. Patient 4: Initial aminoglutethimide was discontinued according to the patient's decision following the achievement of a CR. Low-grade ESS recurrence was observed, and following luteinizing hormone-releasing hormone analog use, the initial treatment was restarted and a CR was achieved once again. Patient 5: Aminoglutethimide was discontinued due to treatment side-effects (asthenia and diarrhea) after 39 months of PR and then letrozole was started, resulting in a CR. Patient 7 was diagnosed with ESS with a sex-cord stromal component at the time of hysterectomy. Patient 18 underwent an anterior exenteration with negative margins, resulting in a CR. Patient 21 was diagnosed with a mix of low-grade ESS and undifferentiated sarcoma. Patient 26 underwent a complete resection of the recurrent tumor following a PR to anastrozole treatment for 9 months and subsequently remained progression-free for 16 months. AI, aromatase inhibitor; ER, estrogen receptor; PR, progesterone receptor; CR, complete response; PR, partial response; SD, stable disease; PD, progression; NED, no evidence of disease; AWD, alive with disease; PC, paclitaxel and cisplatin regimen; BEP, bleomycin, etoposide and cisplatin regimen; DG, docetaxel and gemcitabine regimen; MPA, medroxyprogesterone acetate; MA, megestrol acetate; na, not available; ns, not specified; →, second treatment.
Discussion
ESSs are rare tumors that occur predominantly in premenopausal and perimenopausal women (25) (26) (27) . ESSs are indolent tumors and have long disease-free intervals in the absence of specific therapies, such as estrogen-containing hormone replacement therapy or tamoxifen. The prognosis for low-grade ESS is extremely good, with a 5-year survival rate of >90% (6). However, 40-50% of those individuals with low-grade ESS develop recurrent disease, which often occurs 10-20 years after the initial diagnosis (17, 18) .
ESS resembles proliferating endometrial stroma histologically, typically expressing ERs and PRs, and is regarded as hormone-sensitive. Aromatase inhibitors, progesterone and gonadotropin-releasing hormone agonists have all been suggested as uterine sarcoma treatments. Progestins are the most widely used agents for the treatment of advanced and recurrent ESS (8) . Progestins inhibit estrogen-mediated growth factors, downregulate the ER and increase estrogen metabolism and clearance, thereby decreasing the effects of estrogen on ER-positive cells. Although progestins are an effective medication, they also exhibit various adverse side-effects, including weight gain, depression and thromboembolic events (9).
Aromatase inhibitors have been used in the treatment of breast cancer and are a potential treatment for ESS. Aromatase inhibitors decrease levels of estrogen by peripherally inhibiting estrogen synthesis. First-generation (aminoglutethimide) and second-generation (formestan and fadrozole) aromatase inhibitors were non-specific non-steroidal aromatase inhibitors, which exhibited serious side-effects due to the inhibition of mineralocorticoid and glucocorticoid synthesis (9) . The third-generation non-steroidal aromatase inhibitors exemestane and letrozole, and the steroidal aromatase inhibitor anastrozole, exhibit minimal effects on the adrenal glands and can be orally administered. Several case studies have been published with regard to the efficacy of the aromatase inhibitors aminoglutethimide, letrozole, anastrozole and exemestane in the treatment of advanced low-grade ESS (20, 27) . However, no systemic systematic reviews or prospective studies on aromatase inhibitor treatment for ESS have been published. In the literature review of aromatase inhibitor treatment in patients with low-grade ESS in the present study, the overall response rate was 77.4% and the disease control rate was 90.3%. Additionally, aromatase inhibitors showed similar tumor responses in the second-line or higher treatment setting compared with first-line therapy. Furthermore, aromatase inhibitors, particularly third-generation letrozole, which is the most widely used aromatase inihibitor, are well tolerated during long-term treatment. Together, these data suggest that aromatase inhibitors are effective for the treatment of low-grade ESS and exhibit a favorable toxicity profile.
The present study reports the cases of two patients with residual or recurrent low-grade ESS who experienced long-term disease-free survival following treatment with letrozole. Aromatase inhibitors, particularly the third-generation drugs, are a well-tolerated class of medications that are effective for the treatment of ESS with minimal adverse effects and thus a higher therapeutic window. However, given the rarity of these tumors, data from large, prospective randomized trials are lacking. To address these issues, a large, multicenter, prospective trial is required. Table II . Response rate to AI in evaluable patients with low-grade endometrial stromal sarcoma. Table III . Response rate to first-line (n=13) and second-line or higher (n=18) AIs in evaluable patients with low-grade endometrial stromal sarcoma. 
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